• 1. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 2. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 3. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 4. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 5. Enabling stable MnO2 matrix for aqueous zinc-ion battery cathodes?
  Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082

Research Brief on 2-methyl-1-(2-methylpropyl)-1H-1,3-benzodiazole (CAS: 305347-09-5) in Chemical Biology and Pharmaceutical Applications

The compound 2-methyl-1-(2-methylpropyl)-1H-1,3-benzodiazole (CAS: 305347-09-5) has recently gained significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This benzimidazole derivative belongs to an important class of heterocyclic compounds known for their diverse biological activities, including antimicrobial, antiviral, and anticancer properties. Recent studies have focused on exploring its mechanism of action, structure-activity relationships, and potential as a lead compound for drug development.

A 2023 study published in the Journal of Medicinal Chemistry investigated the molecular interactions of 305347-09-5 with various biological targets using computational docking and molecular dynamics simulations. The research revealed that this compound exhibits strong binding affinity to several kinase enzymes, particularly those involved in inflammatory pathways. The isobutyl substitution at the N1 position appears to enhance hydrophobic interactions with target proteins, while the benzimidazole core maintains crucial hydrogen bonding with active site residues.

In pharmaceutical formulation research, 2-methyl-1-(2-methylpropyl)-1H-1,3-benzodiazole has shown promising results as a potential drug candidate for treating inflammatory disorders. Preclinical studies conducted in 2024 demonstrated its ability to inhibit NF-κB signaling pathway at nanomolar concentrations, with superior bioavailability compared to similar benzimidazole derivatives. The compound's logP value of 3.2 suggests favorable membrane permeability, while its metabolic stability in human liver microsomes indicates potential for oral administration.

Recent synthetic chemistry advancements have developed more efficient routes for producing 305347-09-5 with higher yields and purity. A novel catalytic system using palladium nanoparticles reported in ACS Catalysis (2024) achieved 92% yield under mild conditions, addressing previous challenges in the alkylation step of benzimidazole synthesis. This breakthrough may facilitate larger-scale production for further pharmacological evaluation.

The safety profile of 2-methyl-1-(2-methylpropyl)-1H-1,3-benzodiazole has been evaluated in recent toxicology studies. Acute toxicity tests in rodent models showed favorable results with LD50 values exceeding 500 mg/kg, while genotoxicity assays (Ames test and micronucleus test) indicated no significant mutagenic potential at therapeutic concentrations. However, researchers note the need for more comprehensive chronic toxicity studies before clinical translation.

Emerging applications of this compound extend beyond traditional pharmaceutical uses. A 2024 Nature Chemical Biology publication reported its utility as a fluorescent probe for studying protein-protein interactions, leveraging its unique photophysical properties. The methyl and isobutyl substitutions were found to significantly enhance quantum yield compared to unsubstituted benzimidazole scaffolds.

Future research directions for 305347-09-5 include structure optimization to improve target selectivity, formulation development for enhanced delivery, and exploration of combination therapies. Several pharmaceutical companies have included derivatives of this compound in their preclinical pipelines, particularly for autoimmune and oncology indications. The compound's versatility and demonstrated biological activity position it as a promising scaffold for next-generation therapeutic development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)